(Total Views: 675)
Posted On: 02/07/2025 1:44:51 PM
Post# of 150082
Dr. Jacob Lalezari, CEO of CytoDyn, added, “We are very encouraged by these initial findings, which add to the growing body of evidence that leronlimab’s core mechanism of action, binding to CCR5 receptors on cells, could translate into a variety of meaningful clinical benefits for patients across a number of medical conditions. As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.”
Who would be the right partner?
Identifying the ideal partner for CytoDyn to advance the clinical development of leronlimab in treating liver fibrosis involves considering companies with a strong focus on liver diseases, particularly those with experience in fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). Potential partners include:
Madrigal Pharmaceuticals: Specializing in novel therapeutics for MASH, Madrigal's expertise aligns with CytoDyn's objectives.
IR.MADRIGALPHARMA.COM
Boehringer Ingelheim: With active research in liver fibrosis and recent advancements in MASH treatments, Boehringer Ingelheim could offer valuable collaboration opportunities.
BOEHRINGER-INGELHEIM.COM
Akero Therapeutics: Focused on reversing liver fibrosis in MASH patients, Akero's recent clinical successes highlight its potential as a strategic partner.
BARRONS.COM
Viking Therapeutics: Engaged in developing treatments for liver diseases, including MASH, Viking's pipeline may complement CytoDyn's efforts.
MARKETWATCH.COM
Carisma Therapeutics: Exploring innovative approaches to liver fibrosis treatment, Carisma's research could align with leronlimab's development.
PRNEWSWIRE.COM
Collaborating with these companies could leverage their expertise and resources to further the development of leronlimab for liver fibrosis and related conditions.
Recent Developments in Liver Fibrosis Treatments
barrons.com
Akero Therapeutics Stock Doubles on Liver Data
11 days ago
reuters.com
Novo's trial of weight-loss drug shows improvement in fatty liver disease
98 days ago
marketwatch.com
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
79 days ago
Who would be the right partner?
Identifying the ideal partner for CytoDyn to advance the clinical development of leronlimab in treating liver fibrosis involves considering companies with a strong focus on liver diseases, particularly those with experience in fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). Potential partners include:
Madrigal Pharmaceuticals: Specializing in novel therapeutics for MASH, Madrigal's expertise aligns with CytoDyn's objectives.
IR.MADRIGALPHARMA.COM
Boehringer Ingelheim: With active research in liver fibrosis and recent advancements in MASH treatments, Boehringer Ingelheim could offer valuable collaboration opportunities.
BOEHRINGER-INGELHEIM.COM
Akero Therapeutics: Focused on reversing liver fibrosis in MASH patients, Akero's recent clinical successes highlight its potential as a strategic partner.
BARRONS.COM
Viking Therapeutics: Engaged in developing treatments for liver diseases, including MASH, Viking's pipeline may complement CytoDyn's efforts.
MARKETWATCH.COM
Carisma Therapeutics: Exploring innovative approaches to liver fibrosis treatment, Carisma's research could align with leronlimab's development.
PRNEWSWIRE.COM
Collaborating with these companies could leverage their expertise and resources to further the development of leronlimab for liver fibrosis and related conditions.
Recent Developments in Liver Fibrosis Treatments
barrons.com
Akero Therapeutics Stock Doubles on Liver Data
11 days ago
reuters.com
Novo's trial of weight-loss drug shows improvement in fatty liver disease
98 days ago
marketwatch.com
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
79 days ago
(7)
(0)Scroll down for more posts ▼
